BOT + BAL is advancing as a neoadjuvant immunotherapy for high-risk Stage II/III MSS colon cancer, showing unprecedented efficacy and a favorable safety profile in early trials. A fully funded, FDA-aligned Phase 3 trial is set to begin, targeting a >$7B US market, with key interim data expected in 2027.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.